These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35732976)

  • 21. Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study.
    Lachowiez CA; Reville PK; Kantarjian H; Jabbour E; Borthakur G; Daver N; Loghavi S; Furudate K; Xiao L; Pierce S; Short NJ; Maiti A; Yilmaz M; Sasaki K; Takahashi K; Konopleva M; Pemmaraju N; Popat U; Shpall E; Garcia-Manero G; Ravandi F; DiNardo CD; Kadia TM
    Lancet Haematol; 2022 May; 9(5):e350-e360. PubMed ID: 35483396
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: A single institution experience.
    Gaut D; Burkenroad A; Duong T; Feammelli J; Sasine J; Schiller G
    Leuk Res; 2020 Mar; 90():106314. PubMed ID: 32035355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study.
    Ram R; Amit O; Zuckerman T; Gurion R; Raanani P; Bar-On Y; Avivi I; Wolach O
    Ann Hematol; 2019 Aug; 98(8):1927-1932. PubMed ID: 31187237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
    Schuler E; Wagner-Drouet EM; Ajib S; Bug G; Crysandt M; Dressler S; Hausmann A; Heidenreich D; Hirschbühl K; Hoepting M; Jost E; Kaivers J; Klein S; Koldehoff M; Kordelas L; Kriege O; Müller LP; Rautenberg C; Schaffrath J; Schmid C; Wolff D; Haas R; Bornhäuser M; Schroeder T; Kobbe G;
    Ann Hematol; 2021 Apr; 100(4):959-968. PubMed ID: 33191481
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapy.
    Yamauchi T; Yoshida C; Usuki K; Takada S; Matsumura I; Dobashi N; Miyazaki Y; Miyamoto T; Iida H; Asou N; Kuroda J; Ichikawa S; Komatsu N; Mendes W; Honda H; Okubo S; Kurokawa M; Jiang Q; Wei A; Ishizawa K
    Jpn J Clin Oncol; 2021 Aug; 51(9):1372-1382. PubMed ID: 34322703
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Venetoclax and low-dose cytarabine induced complete remission in a patient with high-risk acute myeloid leukemia: a case report.
    Liu B; Narurkar R; Hanmantgad M; Zafar W; Song Y; Liu D
    Front Med; 2018 Oct; 12(5):593-599. PubMed ID: 29785506
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Analysis of the Efficacy and Prognosis Factors of Acute Myeloid Leukemia with a Combination Therapy of Venetoclax].
    Ren CC; Zhang WW; Wu TK; Liu B
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):104-111. PubMed ID: 38387907
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Venetoclax for the treatment of elderly or chemotherapy-ineligible patients with acute myeloid leukemia: a step in the right direction or a game changer?
    Agarwal S; Kowalski A; Schiffer M; Zhao J; Bewersdorf JP; Zeidan AM
    Expert Rev Hematol; 2021 Feb; 14(2):199-210. PubMed ID: 33459064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FLAG/FLAG-IDA regimen for children with relapsed/refractory acute leukemia in the era of targeted novel therapies.
    Mustafa O; Abdalla K; AlAzmi AA; Elimam N; Abrar MB; Jastaniah W
    J Oncol Pharm Pract; 2019 Dec; 25(8):1831-1838. PubMed ID: 30518307
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.
    Agarwal S; Gopalakrishnan S; Mensing S; Potluri J; Hayslip J; Kirschbrown W; Friedel A; Menon R; Salem AH
    Hematol Oncol; 2019 Oct; 37(4):464-473. PubMed ID: 31251400
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sequential treatment with FLAG-IDA/treosulfan conditioning regimen for patients with active acute myeloid leukemia.
    Shargian-Alon L; Wolach O; Rozovski U; Yahav D; Sela-Navon M; Rubinstein M; Oniashvilli N; Pasvolsky O; Raanani P; Yeshurun M
    Ann Hematol; 2020 Dec; 99(12):2939-2945. PubMed ID: 32892274
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia.
    Byrne M; Danielson N; Sengsayadeth S; Rasche A; Culos K; Gatwood K; Wyatt H; Chinratanalab W; Dholaria B; Ferrell PB; Fogo K; Goodman S; Jagasia M; Jayani R; Kassim A; Mohan SR; Savani BN; Strickland SA; Engelhardt BG; Savona M
    Am J Hematol; 2020 Sep; 95(9):1006-1014. PubMed ID: 32390196
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FLAG-Ida Regimen as Bridge Therapy to Allotransplantation in Refractory/Relapsed Acute Myeloid Leukemia Patients.
    Delia M; Pastore D; Carluccio P; Pasciolla C; Ricco A; Rossi AR; Casieri P; Mestice A; Albano F; Specchia G
    Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):767-773. PubMed ID: 28864170
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real world results of venetoclax combined with hypomethylating agents in relapsed/refractory AML.
    Ucar MA; Ozet G; Koyuncu MB; Sonmez M; Akidan O; Ayli M; Yildirim M; Pehlivan M; Akkurd DM; Sahin H; Guvenc B; Okan V; Tiftik EN; Akdeniz A; Dincyurek HD; Gunes AK; Dagdas S; Acar HI; Ucar HK; Tombak A
    Eur Rev Med Pharmacol Sci; 2021 Nov; 25(21):6557-6565. PubMed ID: 34787859
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant.
    Bewersdorf JP; Derkach A; Gowda L; Menghrajani K; DeWolf S; Ruiz JD; Ponce DM; Shaffer BC; Tamari R; Young JW; Jakubowski AA; Gyurkocza B; Chan A; Xiao W; Glass J; King AC; Cai SF; Daniyan A; Famulare C; Cuello BM; Podoltsev NA; Roshal M; Giralt S; Perales MA; Seropian S; Cho C; Zeidan AM; Prebet T; Stein EM; Tallman MS; Goldberg AD; Stahl M
    Leuk Lymphoma; 2021 Dec; 62(14):3394-3401. PubMed ID: 34477024
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Venetoclax-based combinations for acute myeloid leukemia: optimizing their use in Latin-America.
    Gómez-De León A; Demichelis-Gómez R; Pinedo-Rodríguez A; Enriquez-Vera D; Flores-Jiménez JA; Ceballos-López AA; Rodríguez-Mejorada M; Herrera Riojas MA; Ovilla-Martínez R; Báez-Islas P; Cota-Rangel X; Neme-Yunes Y; Inclán-Alarcón S; López-Flores NJ; Colunga-Pedraza PR; Rodríguez-Zúñiga AC; Gómez-Almaguer D
    Hematology; 2022 Dec; 27(1):249-257. PubMed ID: 35192778
    [No Abstract]   [Full Text] [Related]  

  • 37. Real-world outcomes of frontline venetoclax-based therapy in older adults with acute myeloid leukemia: an analysis utilizing EHR data.
    Hoff FW; Patel PA; Belli AJ; Hansen E; Foss H; Schulte M; Wang CK; Madanat YF
    Leuk Lymphoma; 2023 Jun; 64(6):1123-1128. PubMed ID: 37052347
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-life monocentric experience of venetoclax-based regimens for acute myeloid leukemia.
    Sciumè M; Bosi A; Canzi M; Ceparano G; Serpenti F; De Roberto P; Fabris S; Tagliaferri E; Cavallaro F; Onida F; Fracchiolla NS
    Front Oncol; 2023; 13():1149298. PubMed ID: 37051529
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs.
    Masarova L; DiNardo CD; Bose P; Pemmaraju N; Daver NG; Kadia TM; Chifotides HT; Zhou L; Borthakur G; Estrov Z; Konopleva M; Verstovsek S
    Blood Adv; 2021 Apr; 5(8):2156-2164. PubMed ID: 33885751
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Retrospective, real-life study of venetoclax plus azacitidine or low-dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy.
    Laloi L; Billotey NC; Dumas PY; Paul F; Villate A; Simand C; Fornecker L; Puisset F; Bertoli S; Simonet MB; Laribi K; Houyou D; Santagostino A; Michel C; Guepin GR; Guerineau E; Tabrizi R; Hunault M; Giltat A; Kaphan E; Bulabois C; Cartet E; Rocher C; Lachenal F; Morisset S; Récher C; Pigneux A; Belhabri A; Michallet M; Michallet AS
    Cancer Med; 2023 Mar; 12(6):7175-7181. PubMed ID: 36482507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.